That's not true. Monoclonal antibodies are on the market right now which slow the progression of the disease (by removing amyloid).
Similarly, there were other drugs that lowered cholesterol that didn’t show a significant reduction in coronary events. As we later learned, it’s not nearly as simple as “cholesterol bad.”